Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NAD advises removing Removyl claims

This article was originally published in The Tan Sheet

Executive Summary

Green tea studies fail to substantiate weight-loss claims for Removyl Advanced Formula dietary supplements, the National Advertising Division says in its recommendation to discontinue the claims. NAD July 7 said Removyl Corp. Ltd. argued the product's efficacy is based on botanical ingredients that are purgative and diuretic in nature and on green tea extract, camellia sinensis. The Council of Better Business Bureaus division said evidence does not support specific fast weight-loss claims for Removyl like "You are going to notice that your weight will have dropped by almost one pound in as little as 8 hours." In the inquiry made in its ongoing monitoring program and as part of its initiative with the Council for Responsible Nutrition, NAD recommended limiting future advertising to claims for the benefits of green tea, and the diuretic and purgative properties of botanicals in Removyl. The Henderson, Nev.-based firm said it has not offered the product for sale since April, but it is shipping remaining orders

You may also be interested in...

US FDA Races To List Essential Medicines For Domestic Manufacture By White House Deadline

With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?

ESMO: Pfizer's Lorbrena Makes Case To Claim ALK+ Lung Cancer CROWN

Lorbrena is approved as a second-line treatment for ALK-positive NSCLC but Pfizer believes data from the first-line Phase III CROWN study makes the drug a serious competitor to standard of care Alecensa in the first-line setting.

ESMO: Evidence Piles Up For AZ’s Tagrisso With ADAURA CNS Data

A new analysis of the ADAURA study shows that Tagrisso’s disease-free survival benefits in early stage EGFRm NSCLC are replicated for brain metastases, a common complication with a poor prognosis. Filings and OS data await.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts